

# WOAH Reference Laboratory Reports Activities 2022

## Activities in 2022

This report has been submitted : 7 juin 2023 14:46

### Laboratory Information

<b>Name of disease (or topic) for which you are a designated WOA Reference Laboratory:</b>	Equine Rhinopneumonitis - Equid alphaherpesvirus 1 and 4 associated disease
<b>Address of laboratory:</b>	Maxwell H. Gluck Equine Research Center, 1400 Nicholasville Road, Lexington, KY 40546-0091
<b>Tel.:</b>	+1 859 257 4757
<b>E-mail address:</b>	l.goehring@UKy.edu
<b>Website:</b>	<a href="https://gluck.ca.uky.edu/">https://gluck.ca.uky.edu/</a>
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Prof. Lutz S. Goehring, MS, Ph.D.
<b>Name (including Title and Position) of WOA Reference Expert:</b>	Prof. Lutz S. Goehring, MS, Ph.D.
<b>Which of the following defines your laboratory? Check all that apply:</b>	Academic institution

### TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
Virus Neutralization	yes	yes	no
Direct diagnostic tests		Nationally	Internationally
PCR	yes	yes	

			no
post mortem examination	yes	yes	no
Fluorescent antibody	yes	yes	no

## **TOR2: REFERENCE MATERIAL**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA?H Members?

No

## **TOR3: NEW PROCEDURES**

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

No

## **TOR4: DIAGNOSTIC TESTING FACILITIES**

10. Did your laboratory carry out diagnostic testing for other WOA?H Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA?H Member?

No

## **TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES**

12. Did your laboratory participate in international scientific studies in collaboration with WOA?H Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
complement fixation assay	1 week	training	Irish Equine Centre, Naas, IRELAND	IRELAND

## TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

We collected data on 13 outbreaks of EHV-1/EHM in Germany, Denmark and Sweden. We also collected data on a large-scale EHV-1 abortion outbreak.

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

We published basic information on outbreak characteristics including risk factors for EHM following EHV-1 infection. (Klouth E. et al. 2021 (Pathogens), and 2022 (Viruses)).

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

*Klouth, Zablotzki, Goehring: Apparent Breed Predilection for Equid Herpesvirus-1-Associated Myeloencephalopathy (EHM) in a Multiple-Breed Herd (Pathogens 2021, 10, 535); Klouth, Zablotzki, Petersen, de Bruijn, Gröndahl, Müller, Goehring Epidemiological Aspects of Equid Herpesvirus-Associated Myeloencephalopathy (EHM) Outbreaks. (Viruses 2022, 14, 2576)*

b) International conferences:

c) National conferences:

*Leipziger Tierärztetag 2019; British Equine Veterinary Association conference 2021;*

d) Other (Provide website address or link to appropriate information):

*Podcast on EHV-1 Vaccination - how do they work?  
sponsored by Zoetis -Germany.*

## TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

No

## TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
AAVDL		UKVDL accreditation.jpg

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
PCR	American Association of Veterinary Diagnostic Laboratories

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

containment as directed by IBC protocols

## TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA H?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA H?

No

## TOR10: NETWORK WITH WOA H REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA H Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOA H Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOA H Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOA H Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

TITLE OF THE PROJECT OR CONTRACT	SCOPE	NAME(S) OF RELEVANT WOA H REFERENCE LABORATORIES
terrestrial manual preliminary results	1-we currently update the terrestrial manual. 2-we looked at preliminary project results on	Dr. Ann Cullinane, Irish Equine Centre, Naas,

WOAH Reference Laboratory Reports Activities 2022

technique	latency and epidemiology. 3- I got exposure to 'complement fixation assay' testing	IRELAND
-----------	--	---------

## **TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING**

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

No

## **TOR12: EXPERT CONSULTANTS**

28. Did your laboratory place expert consultants at the disposal of WOAHP?

No

29. Additional comments regarding your report:

Yes

*I frequently consult on outbreak management and intervention, and on individual patient rehabilitation plans.*